



Silicon intake reduces hypercholesterolemia facilitating reverse cholesterol transport through intestinal activation of LXR/ABC transporters pathway in type 2 diabetic rats

Marina Hernández Martín^{1,2}, Rocío Redondo Castillejo^{1,2}, Paula Ortega Menéndez¹, María Martín Bartolomé¹, Alba Martínez García², Juan Manuel Montes Gómez¹, Adrián Macho González³, Jimena Beatriz Hornedo Seijas², Alba Garcimartín¹, Aránzazu Bocanegra¹, M. Elvira López Oliva²

¹ Department of Pharmacology, Pharmacognosy and Botany. Faculty of Pharmacy. Complutense University of Madrid, 28040, Spain


² Departmental Section of Physiology. Faculty of Pharmacy. Complutense University of Madrid, 28040, Spain

³ Department of Nutrition and Food Science. Faculty of Pharmacy. Complutense University of Madrid, 28040, Spain

INTRODUCTION:

- ❖ Dyslipidemia by increased intestinal cholesterol (Chol) absorption is a risk factor in type 2 Diabetes Mellitus (T2DM).
- ❖ Intestinal transporters mediate Chol absorption and are an important therapeutic target to reduce hypercholesterolemia.
- ❖ Silicon intake (Si) has a hypolipemic effect in experimental T2DM models.
- ❖ Could silicon intake modulate Chol transporters levels in duodenum by lowering hypercholesterolemia in T2DM rats?


METHODS:



OBJECTIVES:

- ❖ To evaluate the hypolipemic effects of Si and to characterize duodenal molecular mechanism implicated.
- ❖ To determine if silicon inhibits the intestinal Chol absorption by modulating its reverse transport LXR/ABCG5/8 pathway.

RESULTS:



CONCLUSIONS:

The present study demonstrates that Si consumption might facilitate the cholesterol efflux into feces through upregulating LXR, ABCG5 and ABCG8 expression in duodenum and could be a potentially therapeutic nutritional ingredient for hypercholesterolemia associated to insulin resistance in T2DM treatment.

ACKNOWLEDGMENTS: This study was supported by Spanish project PID2019-103872RB-I00.

